© 2022 Ncardia

icon to open menu
close
  Search
x

Phenotypically relevant human disease models designed for you

Human iPSC disease models recapitulate the profile of human diseases in vitro, providing a physiologically relevant model for the study of pathophysiological mechanisms and for safety and efficacy screening of compounds. Ncardia’s expertise and in-house capabilities facilitate the efficient generation of clinically relevant custom disease models based on iPSC technology.

 

Contact us

Benefits:

  • Phenotypically relevant - Ncardia generates human iPSC-derived disease models that are fully functional and well characterized with clinically relevant readouts
  • Available for high-throughput screening - Our differentiation protocols are optimized for large-scale manufacturing, enabling use of the same batch from beginning to end to minimize variables in the screening
  • Co-developed projects with high success rate - Our expert team works with you in a transparent and collaborative manner to help you meet your objectives and improve your success rate

 

Schematic overview of Ncardia's iPSC sourcing and reprogramming process

Patient-derived, genome-edited and induced disease models

Human iPSC technology is an excellent tool to improve decision-making steps throughout the early stages of drug discovery. The main benefits of using human iPSC in disease modeling are that they retain patient-specific genetic backgrounds, can be genetically engineered and closely mimic human pathophysiology.

Disease modeling based on human iPSC-derived cells has the potential to revolutionize drug discovery. Nonetheless, significant expertise is required to overcome some technical and conceptual difficulties for the widespread implementation of these models in the pharmaceutical and biotechnology industry.

Partnering with a company that has expertise in human iPSC technology, can help fully leverage its advantages.

Solutions

 

Contact our experts for more information:

Contact us

Ncardia has more than 10 years of experience with human iPSCs, in-house state-of-the-art technology and a highly qualified team to guide and assist you along the steps of disease modeling in any therapeutic area.

Click on each of the steps to discover how we can support you:

Cells in dish icon

Sourcing, reprogramming and genome editing

Gene editing icon

Large-scale differentiation

Differentiation icon

Phenotypic screening

Work with your own iPSC lines, our proprietary lines or we assist you sourcing the perfect line for your project

Ncardia offers sourcing of healthy and disease human iPSC lines through established relationships with leading medical centers and consortia. Appropriate ethical approvals, consents, and contracts are in place, so that human iPSC lines from a wide variety of genetic diseases can be acquired on demand.

In-house reprogramming can be performed when requested. We utilize non-integrating methods like Sendai virus or episomal reprogramming.

CRISPR is a highly efficient genome editing tool that can be applied to your human iPSC line of choice. Using this technology, disease models can be derived from healthy human iPSC lines via knock-in, knock-out, or introduction of point mutations. Mutations present in patient-derived iPSC lines can be corrected with the same approach to generate isogenic controls avoiding background-related variability in the screenings.

> Learn more

Choose your desired functional cell type and we adapt the scale to your requirements

Ncardia has established high-quality and reproducible differentiation protocols for a wide range of cell lineages. Generated iPSC lines can be manufactured at large-scale, to minimize variability and enhance assay reproducibility.

> Learn more

 

Fully characterized human iPSC-derived disease models based on clinically relevant readouts

Ncardia develops high-quality assays that are reproducible, predictive, and available for screening at high- and low-throughput. Our scientists define the optimal conditions for each assay and ensure the selection of the most suitable readouts to characterize your disease phenotype.

> Learn more

Explore our Resources

Ncardia’s team has the experience and knowledge needed to successfully generate models for cardiovascular, neurodegenerative, musculoskeletal, and immune diseases and to continuously expand into additional therapeutic areas.

White Paper: Benefits & Key Considerations for the Use of Human iPSC-Derived Disease Models in Drug Discovery

White Paper: Disease Modeling

Benefits & Key Considerations for the Use of Human iPSC-Derived Disease Models in Drug Discovery

> Learn more
Development of a Parkinson's disease model using Ncyte CNS cells

Case Study: Parkinson's Disease

Parkinson’s disease modeling by over-expression of alpha-synuclein pre-formed fibrils

> Learn more
White Paper: Automated cell culture and high-throughput screening of a human iPSC-derived disease model of cardiac hypertrophy

White Paper: HTS & Cardiac Hypertrophy

Automated cell culture and high-throughput screening of a human iPSC-derived disease model of cardiac hypertrophy

> Learn more




Cookie notice

The Ncardia website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognizing you when you return to our website and helping us to understand which sections of the website you find most interesting and useful. Find out more at: Privacy Policy.


I accept cookies I refuse cookies